

IMC-11F8 – ImClone’s Second Generation Antibody

The second generation antibody (IMC-11F8) is a fully human molecule suggesting less hypersensitivity reactions and better scheduling (biweekly) than available with cetuximab (chymERIC).

For the antibody, affinity constant is "very similar binding affinity to cetuximab" (ImClone). IMPORTANT: At ASCO 2006 abstract reported preliminary results from phase I dose escalation - with only had grade I/II rash observed - BUT the presentation at ASCO mentioned two Grade 3 rashes following 1st cycle (~30pts). The drug is now being tested in a single trial: phase II trial in CRC in combination with chemo therapy (clinicaltrials.gov).

The ImClone website where all the scientific papers are published – references only three papers on the second generation cetuximab, and only one discusses the antibody specifically. Very little information is available on this monoclonal and making any non-speculative conclusions is difficult. YM believes that most questions about this antibody could be addressed as follows: "IMC-11F8 is a high affinity antibody and not surprisingly Gr III rash is evident in preliminary results of the phase I dose-escalation trial; Eli Lilly will probably see more rash as they continue testing. ImClone (Eli Lilly) appears muted about the agent, since post-phase I the company only started a single phase II trial.